Evidence map›Paper›PMID 31983316›Full record

ArticleGut microbes2020

Dietary restriction increases protective gut bacteria to rescue lethal methotrexate-induced intestinal toxicity.

Duozhuang Tang, Ting Zeng, Yiting Wang, Hui Cui, Jianying Wu, Bing Zou, Zhendong Tao, Liu Zhang, George B Garside, Si Tao

Open access · goldAbstract read
In one paragraph

Article in Gut microbes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Serum Levels of IFABP2 and Differences inInternational journal of molecular sciences · 2023
    Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Duozhuang TangJiangxi Key Laboratory of Clinical and Translational Cancer Research, Department of Oncology, The Second Affiliated Hospital of Nanchang University , Jiangxi, China.ORCID 0000-0002-7725-205X
Ting ZengJiangxi Key Laboratory of Clinical and Translational Cancer Research, Department of Oncology, The Second Affiliated Hospital of Nanchang University , Jiangxi, China.ORCID 0000-0002-4586-7869
Yiting WangJiangxi Key Laboratory of Clinical and Translational Cancer Research, Department of Oncology, The Second Affiliated Hospital of Nanchang University , Jiangxi, China.ORCID 0000-0001-8599-2165
Hui CuiJiangxi Key Laboratory of Clinical and Translational Cancer Research, Department of Oncology, The Second Affiliated Hospital of Nanchang University , Jiangxi, China.ORCID 0000-0001-5255-322X
Jianying WuJiangxi Key Laboratory of Clinical and Translational Cancer Research, Department of Oncology, The Second Affiliated Hospital of Nanchang University , Jiangxi, China.ORCID 0000-0003-3691-1933
Bing ZouJiangxi Key Laboratory of Clinical and Translational Cancer Research, Department of Oncology, The Second Affiliated Hospital of Nanchang University , Jiangxi, China.ORCID 0000-0001-9941-4796
Zhendong TaoDepartment of Medical Laboratory Medicine, Jiangxi Province Hospital of Integrated Chinese & Western Medicine , Jiangxi, China.ORCID 0000-0002-4188-8603
Liu ZhangIntensive Care Unit, Peking University People's Hospital , Beijing, China.ORCID 0000-0001-9923-260X
George B GarsideLeibniz Institute on Aging - Fritz Lipmann Institute (FLI) , Jena, Germany.ORCID 0000-0002-8772-9616
Si TaoJiangxi Key Laboratory of Clinical and Translational Cancer Research, Department of Oncology, The Second Affiliated Hospital of Nanchang University , Jiangxi, China.ORCID 0000-0001-6956-8516
Nanchang University · CNIntegrated Chinese Medicine (China) · CNLeibniz Institute on Aging - Fritz Lipmann Institute (FLI) · DEPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methotrexate (MTX) is a typical chemotherapeutic drug that is widely used in the treatment of various malignant diseases as well as autoimmune diseases, with gastrointestinal toxicity being its most prominent complication which could have a significant effect on the prognosis of patients. Yet effective ways to alleviate such complications remains to be explored. Here we show that 30% dietary restriction (DR) for 2 weeks dramatically increased the survival rate of 2-month-old female mice after lethal-dose MTX exposure. DR significantly reduced intestinal inflammation, preserved the number of basal crypt PCNA-positive cells, and protected the function of intestinal stem cells (ISCs) after MTX treatment. Furthermore, ablating intestinal microbiota by broad-spectrum antibiotics completely eliminated the protective effect achieved by DR. 16S rRNA gene deep-sequencing analysis revealed that short-term DR significantly increased the

Indexed as

AnimalsAnti-Bacterial AgentsAntimetabolites, AntineoplasticCaloric RestrictionFemaleGastrointestinal MicrobiomeHumansInflammationIntestinal MucosaLacticaseibacillus rhamnosusMethotrexateMiceMice, Inbred C57BLProbioticsRNA, Ribosomal, 16SAnti-Bacterial AgentsAntimetabolites, AntineoplasticMethotrexateRNA, Ribosomal, 16SDietary restrictiongut microbiotaintestinal stem cellsintestinal toxicitymethotrexate

Identifiers

PMID31983316
PMCPMC7524152
OpenAlexW3002779421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.